(Hypertension. 2001;37:1298.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Department of Pharmacology and the Cardiovascular Risk Factor Reduction Unit, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Correspondence to Venkat Gopalakrishnan, PhD, Department of Pharmacology and the CRFRU, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5 Canada. E-mail Gopal{at}Sask.Usask.Ca
| Abstract |
|---|
|
|
|---|
Key Words: insulin nitric oxide vasodilation endothelin endothelium mesenteric arteries
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
1-agonist methoxamine (MTX, 70
µmol/L), either in the presence or absence of the following agents:
(1) a combination of nitric oxide synthase (NOS) inhibitors
N
-nitro-L-arginine
(L-NNA, 100 µmol/L) and
NG-nitro-L-arginine-methylester
(L-NAME, 100 µmol/L) to maximally inhibit the enzyme; (2) a
calcium-activated potassium channel blocker
(KCa), which serves as an
endothelium-derived hyperpolarizing factor [EDHF]
blocker, (tetrabutylammonium [TBA], 0.5 mmol/L); (3) a
cyclooxygenase inhibitor
(indomethacin, 10 µmol/L); (4) an
ETA receptor blocker (BQ123,100 nmol/L); (5) an
ETB receptor blocker (BQ788, 100 nmol/L); and
(6) a combination of ETA and
ETB receptor blockers (BQ123 and BQ788, 100
nmol/L each). Denudation was accomplished as previously
described.26 The MTX-induced
elevation in baseline PP was allowed to stabilize for 20 to 30 minutes
before the remainder of the protocol was conducted. After 20 to 30
minutes, a maximal dose of acetylcholine (ACh) was injected into the
perfusate. A washout was then allowed before insulin perfusion
was initiated. On stabilization of the MTX-constricted baseline,
insulin was added to the perfusate in concentrations of 3.0
pmol/L, 10 pmol/L, 30 pmol/L, 100 pmol/L, 300 pmol/L...3.0 µmol/L
sequentially, and each concentration was perfused for 4 minutes,
resulting in a cumulative response. Single concentrations of insulin
(1.0 nmol/L or 10 nmol/L) and insulin-derived growth factor (IGF)-1
(1.0 nmol/L and 10 nmol/L) or MTX alone was also included in the
perfusate over a period of 1 hour (n=4). To assess the
postinsulin vasodilation capacity of the VSM, a maximal dose of a
direct NO donor, sodium nitroprusside (SNP), was
injected.
Assessment of Endothelin Generation
To assess whether the loss of insulin-induced
vasodilation was attributable to ET, we collected the MVB
perfusate for 10 minutes during both the baseline and MTX
equilibration periods. After this, perfusate was collected
every 10 minutes for 1 hour during exposure to fixed concentrations of
insulin, IGF-1, or MTX as a control. The ET level in the
perfusate was measured with a sensitive enzyme-linked
immunosorbent assay kit as previously
described.27
Reagents
MTX, TBA, L-NNA, L-NAME,
indomethacin, ACh, SNP, and insulin (human USP) were
all purchased from Sigma. Alcohol was used to dissolve
indomethacin at a final concentration of 1/2000 and was
added to all solutions. BQ123 and BQ788 were obtained from American
Peptide. Krebs solution salts were obtained from BDH. The enzyme-linked
immunosorbent assay kit was obtained from Biomedica Gruppe. Amprep
Octadecyl C18 columns were from Amersham.
Statistical Analysis
Cumulative concentration-response curves were
analyzed individually. The results are expressed as the
percentage of vasodilation of MTX-evoked contraction. The potency of
insulin-induced vasodilation was expressed as the negative logarithm of
the half-maximal response (pD2 value). Both
maximal responses and the pD2 were expressed as
mean±SEM. Comparison of mean values among various groups was performed
by ANOVA methodology (Superanova programSAS Institute).
Simultaneous multiple comparisons were examined by
Scheffés F
test.
| Results |
|---|
|
|
|---|
|
|
|
Effects of Treatment on Insulin
Perfusion
Inclusion of inhibitors of
endothelium-mediated vasodilation and contraction in
the perfusion solution did not have any significant effect on the
MTX-induced increase in PP. Endothelial denudation
(P<0.01), NOS inhibition
(P<0.05), and TBA
(P<0.05) reduced the maximal
vasodilator responses to ACh, whereas neither
indomethacin nor ET antagonists had any
effect. Endothelial denudation significantly attenuated
(P<0.01) insulin-induced
vasodilation
(Figure 3A), resulting in both a decrease in the maximal
vasodilation (P<0.01) and a
right shift in the concentration-response curve
(P<0.01;
Table).
NOS inhibition (P<0.01) and
TBA (P<0.05;
Figure 3B) both attenuated insulin-evoked maximal dilation
(Table).
ETA and nonselective ET-receptor blockade
prevented the loss of vasodilation associated with insulin
concentrations starting at 10 nmol/L
(Figure 3C). Neither selective ET-receptor blockade nor
nonselective ET blockade produced any significant change in the potency
or maximal effect of insulin-evoked vasodilation
(Table).
Maximal SNP responses did not differ among the
groups.
|
| Discussion |
|---|
|
|
|---|
Insulin has been shown to have profound effects on the ET system, promoting the release of ET-119 20 21 22 23 24 and upregulating ET receptors on VSM cells.28 29 Incubation of bovine aortic endothelial cells with insulin in vitro increases the production and release of ET-1 within 10 minutes, an effect that was maximal within 1 to 2 hours.19 20 Our results are consistent with these in vitro observations. Insulin also increases ET-1 production in cultured human VSM cells,21 supporting the finding of enhanced ET release in both healthy as well as obese noninsulin-dependent diabetes mellitus human subjects.22 23 The concentration of insulin (10 nmol/L) that evoked significant ET generation in the present study may be relevant to in vivo situations because similar concentrations of plasma insulin have been detected in hyperinsulinemic Zucker obese rats.30 Furthermore, an in vitro study with femoral artery isolated from Wistar rats used a much higher concentration of insulin (300 nmol/L) to demonstrate a significant increase in KCl-induced vascular contractility. This effect of insulin was attenuated by inclusion of either an ET antagonist or ET antiserum.24
ET has an autocrine influence on endothelial-cell ETB receptors, promoting a transient vasodilation through the release of NO.31 However, ETB-selective antagonism failed to attenuate insulin-induced dilation. Because insulin-evoked NO generation has been shown to be dependent on tyrosine kinase/phosphatidylinositol 3-kinase,12 13 it is possible that although present, the transient ETB-receptormediated NO release made a minimal contribution. It is also possible that ET is not being generated in substantial quantities in this vascular bed during the early vasodilatory phase of the response. The inability of ETB receptor blockade to produce a significant shift in the vasodilatory pD2 confirms that NO (and EDHF) activity is functionally independent of the ETB receptor. Although the functional importance of ETB receptors on VSM is thought to be minimal, the characterization of ETB receptors on the rat mesenteric VSM cells helps to explain the ability of BQ788 to attenuate ETB-mediated vasoconstriction.32
Although the existence of a non-EDNO entity that induces vasodilation through TBA-sensitive potassium conductance has been established,33 this is the first report of two endothelium-derived autocoids mediating an insulin-evoked vasodilation. Little is conclusive about EDHF except that it produces vasodilation during NOS inhibition and that its release is probably linked to an increase in intracellular calcium. The vasodilator effect of insulin could not be attributed to its direct effects on VSM cells because no decrease in response to SNP after insulin infusion was noted. Because endothelial denudation prevented an increase in vascular tone, the involvement of an endothelium-derived vasoconstrictor is probable. Because indomethacin did not significantly alter the dynamics of the response, it is unlikely that a cyclooxygenase-dependent factor was responsible. However, because exogenous insulin may augment cardiovascular reactivity to norepinephrine (NE),34 it is possible that the loss of vasodilation was due to the effects of insulin on MTX-induced vasoconstriction. A recent study has indeed demonstrated that incubation with a high dose (715 nmol/L) but not a low dose (715 pmol/L) of insulin increases the vasoconstrictor effect of NE in resistance vessels of spontaneously hypertensive rats.35 This effect was attenuated by ET-receptor blockade, suggesting that enhanced NE responses were at least partially mediated by ET. Accordingly, ET-1 has been reported to enhance adrenergic vasoconstriction,36 suggesting that sympathetic activation in hyperinsulinemic states could be linked to ET.9
This study demonstrates the importance of the endothelium in regulating the vascular effects of insulin. Interestingly, ET-receptor blockade maintains insulin-mediated vasodilation in the presence of hyperinsulinemia, suggesting a role for these agents in hyperinsulinemic hypertension. We have also demonstrated the involvement of both EDNO and EDHF; however, the recruitment of autacoids is dependent on the type of vascular tissue37 as well as on vascular pathology.38 Furthermore, comorbid factors such as hypertriglyceridemia and hypercholesterolemia19 20 21 22 23 39 may contribute to increased ET generation,23 39 40 which in turn could affect EDNO and/or EDHF.39 Because of this complexity of interaction between endothelial factors, more detailed studies of ET blockers in various vascular beds of insulin-resistant models are required.
| Acknowledgments |
|---|
Received August 3, 2000; first decision August 28, 2000; accepted October 13, 2000.
| References |
|---|
|
|
|---|
2.
Baron AD.
Hemodynamic actions of insulin: review.
Am J Physiol. 1994;267:E187E202.
3.
Anderson EA, Mark
AL. The vasodilator action of insulin: implications for the insulin
hypothesis of hypertension.
Hypertension.. 1993;21:136141.
Editorial comment.
4. Feldman RD, Bierbrier GS. Insulin-mediated vasodilatation: impairment with increased blood pressure and body mass. Lancet. 1993;342:707709.[Medline] [Order article via Infotrieve]
5. Sowers JR. Insulin-resistance and hypertension. Mol Cell Endocrinol. 1990;74:C87C89.[Medline] [Order article via Infotrieve]
6. Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR. Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest. 1991;88:12301236.
7. Tirupattur PR, Ram JL, Standley PR, Sowers JR. Regulation of Na+,K(+)-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens. 1993;6:626629.[Medline] [Order article via Infotrieve]
8.
Gros R, Borkowski
KR, Feldman RD. Human insulin-mediated enhancement of vascular
beta-adrenergic responsiveness.
Hypertension. 1994;23:551555.
9. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilatation in normal humans. J Clin Invest. 1991;87:22462252.
10. Mimaki Y, Kawasaki H, Okazaki M, Nakatsuma A, Araki H, Gomita Y. Involvement of calcitonin gene-related peptide (CGRP) receptors in insulin-induced vasodilatation in mesenteric resistance blood vessels of rats. Br J Pharmacol. 1998;123:16841690.[Medline] [Order article via Infotrieve]
11.
Chen YL, Messina
EJ. Dilation of isolated skeletal muscle arterioles by insulin is
endothelium dependent and nitric oxide mediated.
Am J Physiol. 1996;270:H2120H2124.
12. Bertuglia S, Colantuoni A. Insulin-induced arteriolar dilation after tyrosine kinase and nitric oxide synthase inhibition in hamster cheek pouch microcirculation. J Vasc Res. 1998;35:250256.[Medline] [Order article via Infotrieve]
13. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894898.[Medline] [Order article via Infotrieve]
14. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilatation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:11721179.
15. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulins vascular effects in humans. J Clin Invest. 1994;94:25112515.
16.
Cardillo C, Nambi
SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ, Panza JA. Insulin
stimulates both ET and nitric oxide activity in the human forearm.
Circulation. 1999;100:820825.
17.
Scherrer U,
Sartori C. Insulin as a vascular and
sympathoexcitatory hormone: implications for
blood pressure regulation, insulin sensitivity, and
cardiovascular morbidity.
Circulation. 1997;96:41044113.
18.
Sowers JR.
Insulin and insulin-like growth factor in normal and pathological
cardiovascular physiology.
Hypertension. 1997;29:691699.
19.
Oliver FJ, de la
Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, Quertermous T, King GL.
Stimulation of ET-1 gene expression by insulin in
endothelial cells. J
Biol Chem. 1991;266:2325123256.
20. Hu RM, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of ET from bovine endothelial cells. Diabetes. 1993;42:351358.[Abstract]
21. Anfossi G, Cavalot F, Massucco P, Mattiello L, Mularoni E, Hahn A, Trovati M. Insulin influences immunoreactive ET release by human vascular smooth muscle cells. Metabolism. 1993;42:10811083.[Medline] [Order article via Infotrieve]
22. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, Valesini G, De Mattia G, Santucci A. Insulin stimulates ET-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 1995;80:829835.[Abstract]
23. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of ET-1 release in humans. Diabetes. 1996;45:316321.[Abstract]
24.
Nava P, Collados
MT, Masso F, Guarner V. Endothelin mediation of glucose-induced changes
in vascular contractility.
Hypertension. 1997;30:825829.
25. Christensen KL, Mulvany MJ. Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats. J Vasc Res. 1993;30:7379.[Medline] [Order article via Infotrieve]
26. Misurski DA, Tatchum-Talom R, McNeill JR, Gopalakrishnan V. Vanadate-evoked vasorelaxation of the perfused rat mesenteric vascular bed of Sprague-Dawley rats. Life Sci. 2000;67:13691379.[Medline] [Order article via Infotrieve]
27. Quest DW, Gopalakrishnan V, McNeill JR, Wilson TW. Effect of losartan on angiotensin II-mediated endothelin and prostanoid excretion in humans. Am J Hypertens. 2000;13:12881294.[Medline] [Order article via Infotrieve]
28. McDonald D, Bailie J, Archer D, Chakravarthy U. Molecular characterization of ET receptors and the effect of insulin on their expression in retinal microvascular pericytes. J Cardiovasc Pharmacol. 1995;26(suppl 3):S287S289.
29. Hopfner RL, Hasnadka RV, Wilson TW, McNeill JR, Gopalakrishnan V. Insulin increases ET-1-evoked intracellular free calcium responses by increased ET(A) receptor expression in rat aortic smooth muscle cells. Diabetes. 1998;47:937944.[Abstract]
30. Laight DW, Desai KM, Gopaul NK, Anggard EE, Carrier MJ. Special report: prooxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br J Pharmacol. 1999;128:269271.[Medline] [Order article via Infotrieve]
31. Luscher TF. The endothelium as a target and mediator of cardiovascular disease: 1993 Mack Forster Award Lecture: review. Eur J Clin Invest. 1993;23:670685.[Medline] [Order article via Infotrieve]
32. Deng LY, Li JS, Schiffrin EL. Endothelin receptor subtypes in resistance arteries from humans and rats. Cardiovasc Res. 1995;29:532535.[Medline] [Order article via Infotrieve]
33. Adeagbo AS Endothelium-derived hyperpolarizing factor: characterization as a cytochrome P450 1A-linkedmetabolite of arachidonic acid in perfused rat mesenteric prearteriolar bed. Am J Hypertens. 1997;10:763771.[Medline] [Order article via Infotrieve]
34. Gans RO, Bilo HJ, von Maarschalkerweerd WW, Heine RJ, Nauta JJ, Donker AJ. Exogenous insulin augments in healthy volunteers the cardiovascular reactivity to noradrenaline but not to angiotensin II. J Clin Invest. 1991;88:512518.
35. Rizzoni D, Porteri E, Piccoli A, Castellano M, Pasini G, Guelfi D, Muiesan ML, Agabiti Rosei E, High-dose, not low-dose insulin increases the vasoconstrictor effect of norepinephrine in spontaneously hypertensive rats: effects of antihypertensive treatment. J Vasc Res. 1999;36:393403.[Medline] [Order article via Infotrieve]
36. Wong-Dusting HK, La M, Rand MJ. Endothelin-1 enhances vasoconstrictor responses to sympathetic nerve stimulation and noradrenaline in the rabbit ear artery. Clin Exp Pharmacol Physiol. 1991;18:131136.[Medline] [Order article via Infotrieve]
37. Parsons SJ, Hill A, Waldron GJ, Plane F, Garland CJ. The relative importance of nitric oxide and nitric oxide-independent mechanisms in acetylcholine-evoked dilatation of the rat mesenteric bed. Br J Pharmacol. 1994;113:12751280.[Medline] [Order article via Infotrieve]
38.
Pieper GM,
Dondlinger LA. Plasma and vascular tissue arginine are decreased in
diabetes: acute arginine supplementation restores
endothelium-dependent vasodilatation by augmenting cGMP
production. J Pharmacol Exp
Ther. 1997;283:684691.
39. Hopfner RL, Gopalakrishnan V. Review: endothelin: emerging role in diabetic vascular complications. Diabetologia. 1999;42:13831394.[Medline] [Order article via Infotrieve]
40.
Lerman A, Webster
MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, Burnett JC Jr.
Circulating and tissue endothelin immunoreactivity in
hypercholesterolemic pigs.
Circulation. 1993;88:29232928.
This article has been cited by other articles:
![]() |
R. J. Widmer, R. H. Stewart, M. F. Young, J. E. Laurinec, G. A. Laine, and C. M. Quick Application of local heat induces capillary recruitment in the Pallid bat wing Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2007; 292(6): R2312 - R2317. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Sarafidis and G. L. Bakris Insulin and Endothelin: An Interplay Contributing to Hypertension Development? J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 379 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. V. G. Katakam, C. D. Tulbert, J. A. Snipes, B. Erdos, A. W. Miller, and D. W. Busija Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H854 - H860. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Eringa, C. D. A. Stehouwer, G. P. van Nieuw Amerongen, L. Ouwehand, N. Westerhof, and P. Sipkema Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2043 - H2048. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M Gardiner, D. J. R. Nunez, P. G. Baer, K. K. Brown, and T. Bennett Regional Hemodynamic Effects of the N-(2-Benzoylphenyl)-L-tyrosine Peroxisome Proliferator-Activated Receptor-{gamma} Ligand, GI 262570 [(S)-2-(2-Benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyl-2-oxazol-4-yl)ethoxy]phenyl]propionic Acid], in Conscious Rats J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1226 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Eringa, C. D.A. Stehouwer, T. Merlijn, N. Westerhof, and P. Sipkema Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles Cardiovasc Res, December 1, 2002; 56(3): 464 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Verma, A. W. Miller, and D. W. Busija Endothelin Antagonism and Insulin's Vascular Effects * Response: Endothelin Antagonism and Insulin's Vascular Effects Hypertension, December 1, 2002; 40 (6): e12 - e13. [Full Text] [PDF] |
||||
![]() |
A. W. Miller, C. Tulbert, M. Puskar, and D. W. Busija Enhanced Endothelin Activity Prevents Vasodilation to Insulin in Insulin Resistance Hypertension, July 1, 2002; 40(1): 78 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V d'Uscio, M. Barton, S. Shaw, and T. F Luscher Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice Cardiovasc Res, February 1, 2002; 53(2): 487 - 495. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Misurski, R. L. Hopfner, and V. Gopalakrishnan Attenuated Agonist Evoked Vasoconstrictor Responses in the Perfused Mesenteric Vascular Bed of Streptozotocin Diabetic Rats Exp Biol Med, November 1, 2001; 226(10): 940 - 946. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |